American Diversified Holdings Corporation (ADHC-OTC) Revises Projected Cost To Develop Auracis (TM) Migraine Device Therapy

DEL MAR, CA / ACCESSWIRE / October 23, 2018 / ADHC has revised its Projected Cost to Complete Auracis (Tens) Migraine Therapy. The cost of Engineering and Development to FDA Approval Over 2 year Time Frame has been reduced by $500,000 to $1.5 mm.

ADHC is currently working with financial advisors to create a Private Placement Memorandum (PPM). The PPM will contain all relevant information and risk factors available to investors interested in AURACIStm. Initial valuation estimates for AURACIS have been in the $10 mm range. If this valuation holds true ADHC will retain 85 % of the AURACIStm worth an estimated $8.5 mm. The The valuation model is based upon a variety of factors including: cost of development, competitive environment, Alternative therapies or medications, market size (38 mm patients), ease of market penetration, regulatory risk and other factors.

ADHC has completed a "USE OF FUNDS" projected costs analysis for the development of its migraine management therapy AURACIStm. Management has met with medical device engineering firms and have done an exhaustive analysis of the AURACISTM TENS Migraine therapy system including all the patents and patent applications in the US and abroad, patent license agreement, technical engineering schematics, FDA plans, patient study information and other related assets. Current estimates have been lowered $500k to $1.5 mm to complete all prototype development and FDA compliant market image product development clinical use. Barring any unforeseen issues management believes the $1.5 mm budget should be adequate for all proposed costs over a 24month time frame. Brazos Biomedical is currently meeting with institutional investors to devise a financing strategy to successfully bring The AURACIS product to market.

Investors can find a complete overview of all the AURACIS information on the www.BrazosBiomedical.com website.

As a Holding Company ADCH is uniquely suited to expand into other sectors Migraine and other chronic pain conditions are highly attractive is todays current environment.

ADHC will keep shareholders informed as events progress.

ADHC is a holding company that provides executive management, corporate governance, administrative support, financial advice, and introductions to capital sources to various micro-cap private and public companies that have proven revenues and business models.

BRAZOS BIOMEDICAL LLC is a bio device company utilizing electro stimulation for pain management to improve patient outcomes through creative innovation with a core competency in the migraine and headache pain space.

This press release contains forward-looking statements pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements include risks and uncertainties that may cause the Company's plans to change and are in no way intended to guarantee that the Company will be successful in executing its plans. common stock currently trades on the over-the-counter under the symbol ADHC. This press release in no way constitutes any recommendation regarding the securities of ADHC or its affiliates. Any person reading this press release is advised that this release should be considered in the light of all facts and circumstances regarding the business and financial condition and prospects of ADHC, and no reference has been made that this release contains all information.

Contact: adhcinvestor@gmail.com Tel: 858-259-4534

SOURCE: American Diversified Holdings Corp.